Prevalence and Serotype of Streptococcus Pneumoniae Hospitalized Adult With Community-Acquired Pneumonia

NCT05173727 | Completed DMC

• 1 other identifier: 61356
• Study Type: observational
• Target: 355
• Locations: 1 country
• Sites: 1

Brief Summary

Streptococcus Pneumoniae is one of the etiology in severe CAP and accounts for about 60-75% of cases and is likely to be the leading cause of unknown etiologic pneumonia. In Indonesia, studies regarding the prevalence of Streptococcus pneumoniae as the cause of CAP are still very rare. Therefore, there is still a need for further investigation in S. pneumoniae prevalence among hospitalized CAP by utilizing different detection methods in Indonesia. Antibiotics as a therapy of CAP also showed high levels of resistance, meanwhile, early detection of causative pathogen is potentially reducing the incidence of antibiotic resistance and usage of broad-spectrum antibiotics.

Conditions

Pneumonia, Bacterial

Outcome Measures

Primary Outcomes (1)

• Determine the distribution of Streptococcus pneumoniae serotype and its prevalence

  Determine the distribution of Streptococcus pneumoniae serotype and its prevalence isolated from hospitalized adult patients with CAP in Cipto Mangunkusumo Hospital, Jakarta, Indonesia utilizing different methods.

  Through study completion, an average of 2 year.

Secondary Outcomes (1)

• To investigate the antibiotics susceptibility of Streptococcus pneumoniae

  Through study completion, an average of 2 year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The population target is the severe pneumonia patient in ED/ICU/HCU Cipto Mangunkusumo Hospital. The reachable population is moderate and severe CAP in ED/ICU/HCU, Cipto Mangunkusumo Hospital., Jakarta. The research subjects are the reachable population who meet the inclusion and exclusion criteria by consecutive sampling recruitment method

You may qualify if:

• Hospitalized adult ≥ 18 years old
• Moderate to severe CAP (CURB-65 score \> 2 dan ATS/IDSA 2019)

You may not qualify if:

• Have been taking antibiotic more than 24 hours before enrollment.
• Diagnose with non-infectious ARDS disease (such as aspiration pneumonia or cardiogenic pulmonary edema).
• Diagnose with tuberculosis based on clinical or radiological findings.

Sponsors & Collaborators

• Dr Cipto Mangunkusumo General Hospital: lead
• Eijkman Institute for Molecular Biology: collaborator

Study Sites (1)

Cipto Mangunkusumo Hospital - Universitas Indonesia

Jakarta Pusat, Jakarta Special Capital Region, Indonesia

Location

MeSH Terms

Conditions

Pneumonia, Bacterial

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Gurmeet Singh, MD, PhD

  Indonesian Society of Respirology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head Division Respirology and Critical Illness, Internal Medicine Department, Principal Investigator, Respirology and Critical Illness Consultant

Study Record Dates

• First Submitted: December 10, 2021
• First Posted: December 30, 2021
• Study Start: May 15, 2022
• Primary Completion: July 15, 2023
• Study Completion: November 1, 2023
• Last Updated: December 12, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)